Full Breakdown
GLP-1 Weight-Loss Medications Linked to Decreased Physical Activity, Study Finds
6/19/2026, 10:56:45 AM
Study Overview: Decline in Activity After GLP-1 Treatment
Researchers presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Illinois, reported that adults with obesity who lost weight while using GLP-1 receptor agonists—popular medications such as Ozempic, Wegovy, Mounjaro and Zepbound—showed a reduction in daily movement.
Background: GLP-1 Agonists and Expectations for Exercise
GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide and dulaglutide, are prescribed for weight loss. Clinicians and patients often assume that shedding excess weight naturally facilitates greater physical activity. The analysis challenges that expectation.
Study Design and Participant Profile
The investigation used data from the NIH All of Us Research Program, linking electronic health records with Fitbit logs. The initial cohort comprised 1,950 adults with obesity who started a GLP-1 medication. After applying criteria, 753 participants (78.6 % women; mean age 52.7 years) were retained. Researchers compared step counts and moderate-to-vigorous activity (MVPA) before and after medication start.
Data & Statistics: Activity Reductions
- Average daily steps fell from 5,047 to 4,487.
- Average MVPA minutes dropped from 28 to 22 per day.
- The most pronounced declines occurred among men and participants reporting joint or muscle pain.
- Age, heart-failure history, and prior stroke did not modify the trends.
Implications for Health and Muscle Preservation
GLP-1 drugs can reduce lean muscle mass as well as body fat, making sustained exercise essential for preserving strength. Study lead Dr. Sajana Maharjan of HSHS St. John’s Hospital in Springfield, Illinois, emphasized that protecting muscle is essential for healthy weight loss.
Official Statements & Responses
Dr. Maharjan said the findings underscore that exercise should not be considered optional for patients on GLP-1 medications and emphasized the need for targeted programs that promote physical activity alongside drug therapy. She also highlighted that the research represents the first large-scale analysis using wearable fitness-tracker data to assess activity patterns among adults receiving GLP-1 receptor agonists.
Criticism & Opposition: Challenging the Assumption of Automatic Activity Gains
The view that weight loss automatically leads to increased activity is contradicted by the data. Critics argue that without structured support, patients may not translate weight loss into higher activity levels.
Verbatim Quotes
- “People with obesity who lost weight while taking popular medications such as Ozempic, Wegovy, Mounjaro, and Zepbound became significantly less physically active, according to research presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Illinois.” — Study finding
- “Exercise Cannot Be an Afterthought "While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise.” — Dr. Sajana Maharjan, M.D.
- “While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise. The findings in our study reinforce that exercise cannot be optional for people taking these medications. People need targeted interventions that encourage physical activity alongside medication for obesity,” — Dr. Sajana Maharjan, M.D.
- “According to the researchers, this is the first large study to use wearable fitness tracker data to examine physical activity patterns among adults taking GLP-1 receptor agonists.” — Researchers
